Seeking Alpha

Map Pharmaceuticals (MAPP -2.7%) says it plans to meet with the FDA during the current quarter...

Map Pharmaceuticals (MAPP -2.7%) says it plans to meet with the FDA during the current quarter to discuss manufacturing issues that are hindering the approval of its migraine medication Levadex.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|